Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FTRENASDAQ:GHNASDAQ:NTRANASDAQ:RDNT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFTREFortrea$5.32-2.4%$5.22$3.97▼$28.41$493.23M1.591.89 million shs4.33 million shsGHGuardant Health$49.14-2.8%$44.45$20.14▼$52.92$6.27B1.372.14 million shs2.16 million shsNTRANatera$171.86+0.5%$157.00$92.14▼$183.00$23.35B1.741.42 million shs1.52 million shsRDNTRadNet$55.23-3.3%$55.43$45.00▼$93.65$4.29B1.43688,661 shs841,296 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFTREFortrea0.00%-13.08%+16.20%-37.86%-76.65%GHGuardant Health0.00%+3.16%+26.52%+9.70%+68.90%NTRANatera0.00%+4.03%+10.65%+13.12%+58.33%RDNTRadNet0.00%+0.95%-5.05%+15.98%-2.07%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFTREFortrea3.8902 of 5 stars3.91.00.00.02.80.83.8GHGuardant Health3.6459 of 5 stars2.53.00.04.31.52.50.6NTRANatera1.0544 of 5 stars1.52.00.00.02.52.50.6RDNTRadNet3.9841 of 5 stars3.82.00.04.61.52.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFTREFortrea 1.86Reduce$15.00181.95% UpsideGHGuardant Health 3.00Buy$53.769.41% UpsideNTRANatera 3.00Buy$184.637.43% UpsideRDNTRadNet 3.50Strong Buy$69.6026.02% UpsideCurrent Analyst Ratings BreakdownLatest NTRA, GH, FTRE, and RDNT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/13/2025GHGuardant HealthMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$60.00 ➝ $65.006/13/2025RDNTRadNetB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$69.006/12/2025RDNTRadNetB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy ➝ Strong-Buy5/22/2025FTREFortreaCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/15/2025NTRANateraPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$205.00 ➝ $210.005/14/2025FTREFortreaCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/14/2025FTREFortreaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $8.005/14/2025FTREFortreaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$7.00 ➝ $5.005/13/2025FTREFortreaBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$6.00 ➝ $5.005/9/2025NTRANateraUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$211.00 ➝ $218.005/9/2025NTRANateraBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$160.00 ➝ $190.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFTREFortrea$2.70B0.18$1.53 per share3.47$15.19 per share0.35GHGuardant Health$739.02M8.24N/AN/A($1.13) per share-43.49NTRANatera$1.70B13.83N/AN/A$9.05 per share18.99RDNTRadNet$1.83B2.26$3.37 per share16.40$15.31 per share3.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFTREFortrea-$328.50M-$8.79N/A4.160.37-29.43%2.84%1.06%8/11/2025 (Estimated)GHGuardant Health-$436.37M-$3.39N/AN/AN/A-53.82%-1,200.44%-26.77%8/6/2025 (Estimated)NTRANatera-$190.43M-$1.47N/AN/AN/A-10.36%-18.29%-11.68%8/14/2025 (Estimated)RDNTRadNet$2.79M-$0.43N/A104.21N/A-1.73%1.41%0.48%8/6/2025 (Estimated)Latest NTRA, GH, FTRE, and RDNT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025FTREFortrea-$0.07$0.02+$0.09-$6.25$609.63 million$651.30 million5/8/2025Q1 2025NTRANatera-$0.59-$0.50+$0.09-$0.50$446.68 million$501.83 million4/30/2025Q1 2025GHGuardant Health-$0.57-$0.49+$0.08-$0.77$189.91 million$203.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFTREFortreaN/AN/AN/AN/AN/AGHGuardant HealthN/AN/AN/AN/AN/ANTRANateraN/AN/AN/AN/AN/ARDNTRadNetN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFTREFortrea1.220.970.97GHGuardant HealthN/A4.113.76NTRANateraN/A3.873.74RDNTRadNet0.872.012.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFTREFortreaN/AGHGuardant Health92.60%NTRANatera99.90%RDNTRadNet77.90%Insider OwnershipCompanyInsider OwnershipFTREFortrea0.38%GHGuardant Health6.10%NTRANatera7.60%RDNTRadNet5.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFTREFortrea15,50090.50 million90.16 millionOptionableGHGuardant Health2,021123.89 million116.33 millionNot OptionableNTRANatera4,434136.55 million126.17 millionOptionableRDNTRadNet11,02175.03 million70.83 millionOptionableNTRA, GH, FTRE, and RDNT HeadlinesRecent News About These CompaniesRadNet (NASDAQ:RDNT) Might Be Having Difficulty Using Its Capital EffectivelyJune 20 at 11:43 AM | finance.yahoo.comRadNet, Inc. (NASDAQ:RDNT) Receives $69.60 Consensus Target Price from AnalystsJune 18 at 1:27 AM | americanbankingnews.comB. Riley Initiates Coverage on RadNet (NASDAQ:RDNT)June 16, 2025 | americanbankingnews.comRadNet, Inc. (NASDAQ:RDNT) Given Consensus Rating of "Strong Buy" by AnalystsJune 15, 2025 | marketbeat.comRadNet (NASDAQ:RDNT) Upgraded by B. Riley to Strong-Buy RatingJune 14, 2025 | marketbeat.comRadNet (NASDAQ:RDNT) Coverage Initiated by Analysts at B. RileyJune 13, 2025 | marketbeat.com1 of Wall Street’s Favorite Stock with Promising Prospects and 2 to Be Wary OfJune 12, 2025 | msn.comRadNet, Inc. Secures $100 Million Incremental Term Loan to Support Strategic Growth InitiativesJune 11, 2025 | quiverquant.comRadNet Secures $100 Million Incremental Term Loan to Fund Acquisitions and Corporate InitiativesJune 11, 2025 | globenewswire.comGAMMA Investing LLC Buys 80,396 Shares of RadNet, Inc. (NASDAQ:RDNT)June 11, 2025 | marketbeat.comRadNet, Inc. (NASDAQ:RDNT) is Harbor Capital Advisors Inc.'s 4th Largest PositionJune 10, 2025 | marketbeat.comE. Ohman J or Asset Management AB Buys 5,300 Shares of RadNet, Inc. (NASDAQ:RDNT)June 7, 2025 | marketbeat.comRDNT Q1 Earnings Call: Severe Weather Disruptions and Ongoing Shift to Advanced Imaging Highlight ResultsJune 6, 2025 | msn.comRadNet Acquires See-Mode Technologies to Enhance AI Ultrasound ImagingJune 5, 2025 | insidermonkey.comRadNet Acquires Ultrasound Firm See-Mode TechnologiesJune 4, 2025 | marketwatch.comRadNet, Inc. Acquires See-Mode Technologies for Innovation in AI-Powered Ultrasound DiagnosticsJune 4, 2025 | globenewswire.comWellington Management Group LLP Trims Stake in RadNet, Inc. (NASDAQ:RDNT)June 1, 2025 | marketbeat.comRadNet (NASDAQ:RDNT) Stock Price Up 4.3% - Here's WhyMay 31, 2025 | marketbeat.comTwo Sigma Advisers LP Acquires 16,500 Shares of RadNet, Inc. (NASDAQ:RDNT)May 31, 2025 | marketbeat.comRadNet, Inc. (NASDAQ:RDNT) EVP Alma Gregory Sorensen Sells 55,000 SharesMay 30, 2025 | marketbeat.comRadNet’s SWOT analysis: imaging leader’s stock navigates growth and challengesMay 29, 2025 | uk.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsAmong the Market’s Most Shorted: 2 Firms With +40% Short InterestBy Leo Miller | June 3, 2025View Among the Market’s Most Shorted: 2 Firms With +40% Short InterestPalantir Scores First $1 Billion Contract; Is It Priced In?By Chris Markoch | May 27, 2025View Palantir Scores First $1 Billion Contract; Is It Priced In?Why Super Micro Computer's Upside Could Trigger a Short SqueezeBy Gabriel Osorio-Mazilli | June 3, 2025View Why Super Micro Computer's Upside Could Trigger a Short SqueezeNTRA, GH, FTRE, and RDNT Company DescriptionsFortrea NASDAQ:FTRE$5.32 -0.13 (-2.39%) Closing price 04:00 PM EasternExtended Trading$5.48 +0.16 (+3.01%) As of 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.Guardant Health NASDAQ:GH$49.14 -1.43 (-2.83%) Closing price 04:00 PM EasternExtended Trading$49.68 +0.53 (+1.09%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.Natera NASDAQ:NTRA$171.86 +0.88 (+0.51%) Closing price 04:00 PM EasternExtended Trading$171.86 +0.00 (+0.00%) As of 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.RadNet NASDAQ:RDNT$55.23 -1.89 (-3.31%) Closing price 04:00 PM EasternExtended Trading$55.24 +0.01 (+0.01%) As of 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
